Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-24-Q-9404
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) Defense Health Agency is issuing a Request for Quotation (RFQ) for the DoD Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program. The RFQ solicits pricing and discount quotes from pharmaceutical manufacturers for newly approved drugs across several therapeutic drug classes. These quotes will be evaluated by the DoD Pharmacy and Therapeutics (P&T) Committee in November 2024 to determine formulary placement and cost-sharing tier classification. Quotes are due by October 16, 2024, and a pre-quotation teleconference is scheduled for October 2, 2024. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements based on the P&T Committee's decisions.
This is an unrestricted competition with no set-aside. The contracting office is located in San Antonio, TX. The RFQ does not identify any potential incumbent contractors. The contract values will be determined based on the P&T Committee's formulary decisions and the pricing/discount quotes received from manufacturers. The RFQ covers a variety of newly approved drugs across several therapeutic classes, including corticosteroids, ADHD agents, antihypertensives, and oncology agents.
Notice text
2 versions
Update #2 · Latest ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2024: The following newly approved drugs will be reviewed:
a. Aqneursa - Neurological Agents Miscellaneous - N/A
b. Clobetasol Propionate - Ophthalmic - Corticosteroids
c. Cobenfy - Antipsychotic Agents - Atypical
d. Ebglyss - ATOPY - NA
e. Femlyv - Contraceptive Agents - Multiple
f. Lazcluze - Oncological Agents - Multiple
g. Onyda XR - ADHD Agents - Non-Stimulants
h. Tryvio - Antihypertensive Agents - Endothelin Receptor Antagonists
i. Yorvipath - Osteoporosis Agents - PTH Analogs
The RFQ, including UF BPA and UF ADP appendices are attached here. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9404.
Pre-quotation teleconference is on October 2, 2024. Details are stated in Part 2.4. Pre-Quotation Teleconference. Contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3.1), no later than the date stated in Part 2.3.
Update #1 ·
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2024: The following drug newly approved drugs will be reviewed:
a. Clobetasol Propionate - Ophthalmic - Corticosteroids
b. Ebglyss - ATOPY - NA
c. Femlyv - Contraceptive Agents - Multiple
d. Lazcluze - Oncological Agents - Multiple
e. Onyda XR - ADHD Agents - Non-Stimulants
f. Tryvio - Antihypertensive Agents - Endothelin Receptor Antagonists
g. Yorvipath - Osteoporosis Agents - PTH Analogs
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9404.
Pre-quotation teleconference is on October 2, 2024. Details are stated in Part 2.4. Pre-Quotation Teleconference. Contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3.1), no later than the date stated in Part 2.3.
Files
| File | Type | Posted |
|---|---|---|
| Price List - Aqneursa - Neurological Agents Misc - NA.xlsx | XLSX spreadsheet | |
| Amendment 0001.pdf | ||
| Price List - Cobenfy - Antipsychotic Agents - Atypical.xlsx | XLSX spreadsheet | |
| Price List Ebglyss - ATOPY - NA.xlsx | XLSX spreadsheet | |
| RFQ HT9402-24-Q-9404 NAD.pdf | ||
| Price List Clobetasol Propionate - Ophthalmic - Corticosteroids.xlsx | XLSX spreadsheet | |
| Price List Lazcluze - Oncological Agents - Multiple.xlsx | XLSX spreadsheet | |
| Price List Yorvipath - Osteoporosis Agents - PTH Analogs.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List Femlyv - Contraceptive Agents - Multiple.xlsx | XLSX spreadsheet | |
| Price List Onyda XR - ADHD Agents - Non-Stimulants.xlsx | XLSX spreadsheet | |
| Price List Tryvio - Antihypertensive Agents - Endothelin Receptor Antagonists.xlsx | XLSX spreadsheet |
Show all 13
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity